DE false 0001597553 0001597553 2025-03-03 2025-03-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 3, 2025

 

 

Sage Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   001-36544   27-4486580

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

55 Cambridge Parkway

Cambridge, MA

   02142
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (617) 299-8380

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   SAGE   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Medical Officer

On March 3, 2025, Laura Gault, M.D., Ph.D. notified Sage Therapeutics, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company, effective March 21, 2025, to pursue a new opportunity. Dr. Gault’s resignation is not a result of any disagreement with the Company.

 

Item 8.01

Other Events.

Mike Quirk, Ph.D., the Company’s current Chief Scientific Officer, will assume key responsibilities, including strategic guidance for the Company’s clinical development programs, on an interim basis following the effective date of Dr. Gault’s resignation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 4, 2025       SAGE THERAPEUTICS, INC.
    By:  

/s/ Gregory Shiferman

      Gregory Shiferman
      Senior Vice President, General Counsel
v3.25.0.1
Document and Entity Information
Mar. 03, 2025
Cover [Abstract]  
Entity Incorporation State Country Code DE
Amendment Flag false
Entity Central Index Key 0001597553
Document Type 8-K
Document Period End Date Mar. 03, 2025
Entity Registrant Name Sage Therapeutics, Inc.
Entity File Number 001-36544
Entity Tax Identification Number 27-4486580
Entity Address, Address Line One 55 Cambridge Parkway
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 299-8380
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol SAGE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Sage Therapeutics (NASDAQ:SAGE)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Sage Therapeutics.
Sage Therapeutics (NASDAQ:SAGE)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Sage Therapeutics.